The Shareholders Foundation announces that a deadline is coming up on April 14, 2017 in the lawsuit filed for certain investors in NYSE:USNA shares concerning alleged violations of securities laws by USANA Health Sciences, Inc.
Investors who purchased shares of USANA Health Sciences, Inc. (NYSE:USNA) have certain options and there are strict and short deadlines running. Deadline: April 14, 2017. UNYSE:USNA stockholders should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
On August 16, 2010, USANA Health Sciences, Inc. announced that it had acquired BabyCare Ltd. , a China-based manufacturing company that develops and sells nutritional products primarily for infants.
Over the next six years, USANA Health Sciences, Inc. steadily expanded BabyCare Ltd.’s market presence in China.
In February 2013, the Company announced that it had received official government approval from the Ministry of Commerce People’s Republic of China (“MOFCOM”) for direct selling activities in the provinces of Jiangsu and Shaanxi, and the municipality of Tianjin.
In May 2016, USANA Health Sciences, Inc. announced Ministry of Commerce People’s Republic of China approval for direct selling activities in the provinces of Liaoning, Shandong, Shanxi, Sichuan, and Guangdong, as well as the municipalities of Dalian, Qingdao, and Shenzhen.
According to the complaint filed in the U.S. District Court for the District of Utah the plaintiff alleges on behalf of purchasers of USANA Health Sciences, Inc. (NYSE:USNA) common shares between March 14, 2014 and February 7, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 14, 2014 and February 7, 2017, the defendants made false and/or misleading statements and/or failed to disclose that the Company’s BabyCare subsidiary had engaged in improper reimbursement practices in China, that these practices constituted violations of the Foreign Corrupt Practices Act (“FCPA”), that as such, the Company’s China revenues were in part the product of unlawful conduct and unlikely to be sustainable, that the foregoing conduct, when it became known, was likely to subject the Company to significant regulatory scrutiny, and that as a result of the foregoing, USANA Health Sciences’ public statements were materially false and misleading at all relevant times.
USANA Health Sciences, Inc. reported that its Total Revenue rose from $918.50 million for the 12 months period that ended on January 2, 2016 to over $1 billion for the 12 months period that ended on December 21, 2016 and that its Net Income for those time periods increased from $94.67 million to $100.04 million.
On February 7, 2017, post-market, USANA Health Sciences, Inc. disclosed that “[t]he Company is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. . . . focus[ing] on the compliance with the Foreign Corrupt Practices Act . . . and certain conduct and policies at BabyCare, including BabyCare’s expense reimbursement policies.”
USANA Health Sciences, Inc. advised investors that the company had retained outside counsel to conduct the investigation and had notified both the Securities and Exchange Commission and the Department of Justice of the investigation. Shares of USANA Health Sciences, Inc. (NYSE:USNA) declined from $63.45 per share on February 7, 2016 to as low as $54.25 per share on February 8, 2017.
Those who purchased NYSE:USNA shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego